So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

ByInvesting.com • Oct 25, 2024 Viking Therapeutics stock holds Buy rating with focus on upcoming oral VK2735 data at Obesity Week On Thursday, BTIG maintained a Buy rating on Viking Therapeutics ...

Viking Therapeutics (VKTX) is up more than +5% after the company’s experimental pill, VK2735, showed weight loss in patients at higher doses with limited side effects. Air Transport Services Group ...

Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

At Mar-a-Lago, ‘Uncle’ Elon Musk Puts His Imprint on the Trump Transition He’s on the patio. He’s on the golf course. Everywhere President-elect Trump looks, there is the world’s richest ...